Rapid Treatment Needed to Reduce Mortality From Flu-Linked Acute Necrotizing Encephalopathy in Children
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 4, 2025 -- Influenza-associated acute necrotizing encephalopathy (ANE) in children is associated with high morbidity and mortality, according to a study published online July 30 in the Journal of the American Medical Association.
In a multicenter case series, Andrew Silverman, M.D., from Stanford University in Palo Alto, California, and colleagues examined the clinical presentation, interventions, and outcomes among U.S. children diagnosed with influenza-associated ANE.
Overall, 41 of 58 submitted cases from 23 U.S. hospitals met the inclusion criteria. The researchers found that 31 cases (76 percent) had no significant medical history and five (12 percent) were medically complex. Clinical presentation included fever, encephalopathy, and seizures (93, 100, and 68 percent, respectively). Fifteen (47 percent) of the 32 patients with genetic testing had genetic risk alleles potentially related to the risk for ANE, including 11 (34 percent) with RANBP2 variants. Only six (16 percent) of 38 patients with available vaccination history had received age-appropriate seasonal influenza vaccination. Most patients received multiple immunomodulatory treatments, including methylprednisolone, intravenous immunoglobulin, tocilizumab, plasmapheresis, anakinra, and intrathecal methylprednisolone (95, 66, 51, 32, 5, and 5 percent, respectively). The median intensive care unit stay was 11 days and median hospital length of stay was 22 days. Eleven patients died (27 percent) at a median of three days from symptom onset, including 91 percent from cerebral herniation. Sixty-three percent of the 27 survivors with 90-day follow-up had at least moderate disability.
"We saw that critical-care management of brain swelling, along with immune modulating therapies such as plasma exchange and intravenous immunoglobin, appeared helpful for patients who recovered," co-senior author Thomas LaRocca, M.D., Ph.D., also from Stanford University, said in a statement.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted August 2025
Read this next
2020 to 2024 Saw Drop in Flu Vaccine Uptake Among U.S. Adults
FRIDAY, July 18, 2025 -- There was an overall decrease in influenza vaccine uptake among U.S. adults from 2020 to 2024, according to a study published online July 16 in PLOS...
Wildfire-Induced Changes in Behavior Affect Spread of Airborne Disease
WEDNESDAY, June 25, 2025 -- Wildfire-induced deterioration of air quality leads to a substantial increase in indoor activities, fostering conditions conducive to transmission of...
Combined Flu, SARS-CoV-2 Vaccine as Effective as Individual Vaccines for Older Adults
FRIDAY, May 9, 2025 -- mRNA-1083 vaccine is noninferior and induces higher immune responses than recommended influenza and COVID-19 vaccines against several influenza strains and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.